ETC
PRLD icon

Exchange Traded Concepts’s Prelude Therapeutics PRLD Stock Holding History

Exchange Traded Concepts’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,409
Closed -$82.1K – 1419
2024
Q4 		$82.1K Hold
64,409
– – ﹤0.01% 1178
2024
Q3 		$133K Buy
64,409
+15,682
+32% +$72.6K ﹤0.01% 1101
2024
Q2 		$186K Sell
48,727
-15,160
-24% -$61.7K ﹤0.01% 885
2024
Q1 		$303K Buy
63,887
+19,800
+45% +$77K 0.01% 792
2023
Q4 		$188K Buy
44,087
+11,180
+34% +$34K 0.01% 794
2023
Q3 		$102K Buy
32,907
+7,479
+29% +$28.1K ﹤0.01% 886
2023
Q2 		$114K Buy
+25,428
New +$152K ﹤0.01% 921

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exchange Traded Concepts's PRLD Position: Q1 2025 in Review

Exchange Traded Concepts sold out of Prelude Therapeutics (PRLD) in Q1 2025, closing a stake of 64,409 shares — an estimated $82.1K sold.

Exchange Traded Concepts first reported a position in PRLD in Q2 2023 and held it in 7 quarters. The position peaked at $303K in Q1 2024. 59 funds tracked by Wall St. Rank hold PRLD as of Q1 2025.

  • Exchange Traded Concepts reported no remaining Prelude Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 64,409 Prelude Therapeutics shares in Q1 2025, an estimated $82.1K.
  • Exchange Traded Concepts first reported a position in Prelude Therapeutics in Q2 2023 and held it in 7 quarters.
  • Exchange Traded Concepts's Prelude Therapeutics position peaked at $303K in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2025.

Based on Exchange Traded Concepts's 13F filing for Q1 2025, filed 17 Apr 2025.